Bozic M, Diaz-Tocados JM, Bermudez-Lopez M, et al. - This study was attempted to investigate the possible independent effects of secondary hyperparathyroidism (SHPT) (defined as patients with excessive PTH levels or on treatment with PTH decreasing agents) on the risk of chronic kidney disease (CKD) progression and cardiovascular events (CVE) incidence in CKD patients, as well as if hypercalcemia and/or hyperphosphatemia act as effect modifiers. Researchers recruited a total of 2,445 CKD patients without previous CVE from the NEFRONA cohort (950 stage 3, 612 stage 4, 195 stage 5, and 688 on Dialysis). The risk of patients suffering CKD progression or a CVE was ascertained by using Multivariate logistic and Fine and Gray regression analysis. It was shown that in CKD patients, SHPT and hyperphosphatemia are independently correlated with CKD progression and the incidence of CVE.